Leerink Swann & Company: Leerink Swann & Company Initiates Coverage of Forest Laboratories, Inc. (NYSE: FRX)
29th Sep 2005, 15:52 GMT
BOSTON, MA (MARKET WIRE) This morning, Senior Specialty Pharmaceuticals Analyst, Gary Nachman, initiated coverage of Forest Laboratories, Inc. (NYSE: FRX) with a Market Perform rating. He believes the risk/reward profile does not justify owning the stock at these levels. Lexapro accounts for roughly two-thirds of sales and has a number of clouds hanging over it, most notably generic litigation.
Latest news from Market Wire - Pharmaceuticals and Biotech:
- Qiagen N.V.: QIAGEN Introduces Novel Technology for Customized RNAi Assay Products
- IBEX TECHNOLOGIES INC.: IBEX: Analysis of Urinary C2C Distinguishes Between Individuals with Painful Knees and Individuals Identified by MRI to Have Early Osteoarthritis
- Daiichi Sankyo, Inc.: First Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds Additional Lipid Parameter Benefits
- Daiichi Sankyo, Inc.: WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions
- Targeted Genetics Corporation: Interim Data on Use of tgAAC94 in the Treatment of Inflammatory Arthritis Presented at the American College of Rheumatology Meeting
- Crucell N.V.: Crucell Announces Third Quarter 2006 Results
- Acambis PLC: Acambis PLC announces Update on US MVA procurement
- SkyePharma PLC: SkyePharma PLC announces Board Appointment
- Base Technologies, Inc.: Base Technologies Award of Air Force Surgeon General Contract Continues Rapid Growth Trend
- Eugene Science, Inc.: Eugene Science Signs Major Distribution Agreement With RexGene Biotech